Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/209294
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSalgüero Fernández, Sergio-
dc.contributor.authorGabriel Medina, Pablo-
dc.contributor.authorAlmería Lafuente, Alejandro-
dc.contributor.authorBallesteros Vizoso, María Antonieta-
dc.contributor.authorZamora Trillo, Angielys-
dc.contributor.authorCasals Mercadal, Gregori-
dc.contributor.authorSolé Enrech, Gemma-
dc.contributor.authorLalana Garcés, Marta-
dc.contributor.authorGuerra Ruiz, Armando R.-
dc.contributor.authorOrtiz Pastor, Oihana-
dc.contributor.authorMorales Ruiz, Manuel-
dc.date.accessioned2024-03-27T13:31:01Z-
dc.date.available2024-03-27T13:31:01Z-
dc.date.issued2023-07-11-
dc.identifier.issn2628-491X-
dc.identifier.urihttps://hdl.handle.net/2445/209294-
dc.description.abstractIntroduction: Abnormal liver biochemistry is not a rare finding in the context of SARS-CoV-2 infection, regardless of patients having pre-existing chronic disease or not Content: This review examines the current body of knowledge on the relationship between COVID-19 and liver injury, which is frequently found in this setting Summary: Although the pathogenesis of liver injury is not fully understood, it has been suggested to be the result of a combination of multiple factors. These include direct injury caused by the virus, immune system hyperactivation, ischemic and drug-induced injury. The prognostic valor of these alterations is also the subject of intense research. Due to their potential impact, these alterations require proper management and treatment, especially in patients with chronic liver disease or liver transplant recipients. Outlook: Some aspects associated with liver injury during COVID-19, especially in severe presentations, are not well understood. Studies assessing the clinical impact of COVID-19 on the healthy or diseased liver may help adjust treatment and immunization guidelines to the profile of the patient. © 2022 Sergio Salgüero Fernández et al., published by De Gruyter, Berlin/Boston.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWalter De Gruyter Gmbh-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1515/almed-2022-0037-
dc.relation.ispartofAdvances In Laboratory Medicine, 2022, vol. 3, num. 2, p. 126-133-
dc.relation.urihttps://doi.org/10.1515/almed-2022-0037-
dc.rightscc by (c) Salgüero Fernández, Sergio et al, 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)-
dc.subject.classificationMalalties del fetge-
dc.subject.classificationSARS-CoV-2-
dc.subject.otherLiver diseases-
dc.titleImpact of SARS-CoV-2 infection on liver disease-
dc.typeinfo:eu-repo/semantics/other-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-07-11T07:54:18Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.idimarina9330064-
dc.identifier.pmid37361869-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
Impact of SARS-CoV-2 infection on liver disease_AdvLabMed.pdf876.9 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons